title: Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
abstract: OBJECTIVE
  We assessed the effectiveness and safety of an induction dose of peginterferon alfa-2b (PEG-IFN) plus ribavirin for initial treatment of patients with genotype 1 chronic HCV infection in a randomized, controlled, multicenter trial.
  
  
  METHODS
  Three hundred and eleven naïve patients infected with genotype 1 and chronic hepatitis were randomly assigned to 48-week treatment with PEG-IFN once weekly (80-100 micrograms depending on body weight for 8 weeks, followed by 50 micrograms for the next 40 weeks), or standard interferon alfa-2b (IFN) 6 million units on alternate days, both in combination with ribavirin (1000-1200 mg/day).
  
  
  RESULTS
  PEG-IFN plus ribavirin significantly increased sustained virological response (SVR) compared with IFN plus ribavirin (41.1 vs. 29.3% respectively, P=0.030). Less patients discontinued PEG-IFN than IFN (19 vs. 31%, P=0.010). By logistic regression, SVR in the PEG-IFN group was independently associated with age <50 years, and mild fibrosis at liver biopsy.
  
  
  CONCLUSIONS
  Combination therapy with an induction dose of PEG-IFN was a more effective and better tolerated treatment for naïve patients with genotype 1 than combination therapy with high dose standard IFN. In patients aged less than 50 years with mild fibrosis this schedule achieves a very high rate of SVR.
authors.affiliation: Clinica Medica, Ospedale San Paolo and Liver Unit, Ospedale Fatebenefratelli e Oftalmico, Milano, Italy.
authors.forename: Savino
authors.initials: S
authors.lastname: Bruno
authors.forename: Calogero
authors.initials: C
authors.lastname: Cammà
authors.forename: Vito
authors.initials: V
authors.lastname: Di Marco
authors.forename: Mariagrazia
authors.initials: M
authors.lastname: Rumi
authors.forename: Maria
authors.initials: M
authors.lastname: Vinci
authors.forename: Mario
authors.initials: M
authors.lastname: Camozzi
authors.forename: Chiara
authors.initials: C
authors.lastname: Rebucci
authors.forename: Danilo
authors.initials: D
authors.lastname: Di Bona
authors.forename: Massimo
authors.initials: M
authors.lastname: Colombo
authors.forename: Antonio
authors.initials: A
authors.lastname: Craxì
authors.forename: Mario U
authors.initials: MU
authors.lastname: Mondelli
authors.forename: Giovanbattista
authors.initials: G
authors.lastname: Pinzello
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004361:Drug Tolerance; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D012449:Safety
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b